Barclays Maintains Overweight on 10x Genomics, Raises Price Target to $66
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Luke Sergott maintains an Overweight rating on 10x Genomics (NASDAQ:TXG) and raises the price target from $65 to $66.
August 04, 2023 | 3:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays maintains an Overweight rating on 10x Genomics and raises the price target from $65 to $66, indicating a positive outlook for the company.
The raised price target by Barclays indicates their belief in the company's potential for growth. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100